Otero Jose Manuel 4

What Happened Jose Manuel Otero, Chief Operating Officer of Lexeo Therapeutics (LXEO), reported a sale of 1,302 shares on 2026-05-18. The shares were disposed in an open-market transaction at a weighted average price of $5.07 per share, for total proceeds of approximately $6,606. The filing notes this sale was to satisfy tax-withholding obligations associated with the release of restricted stock units (RSUs), which is a routine, non-speculative transaction.

Key Details

• Transaction type: Sale (S) — Open market/private sale to cover taxes on RSU release (Footnote F1).
• Date: 2026-05-18; prices ranged from $5.06 to $5.11 across multiple trades; reported weighted average $5.07 (Footnote F2).
• Proceeds: Approximately $6,606 (1,302 shares × $5.07).
• Holdings after transaction: Reported holdings include 100,621 Restricted Stock Units (Footnote F3).
• Filing timeliness: Reported on 2026-05-20; appears filed within the standard Section 16 reporting window (not flagged late).

Context Sales to cover tax withholding on RSU vesting are common and do not necessarily indicate a change in an insider's view of the company. The filing discloses that multiple trade prices were aggregated to a weighted average; the filer has offered to provide per-trade details to SEC staff or shareholders on request.